Genenta Science SpA ADR

Genenta Science SpA ADR EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Genenta Science SpA ADR (GNTA) as of Nov 3, 2026 is -2.76. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -4.30 — a change of -35.89% (higher).

EV/FCF

-2.76

YoY

-35.89%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Genenta Science SpA ADR is 2025 -2.76 . EV/FCF (Enterprise Value to Free Cash Flow) of Genenta Science SpA ADR was 2024 -4.30 . It decreases by -35.89% higher compared to the previous year.

The Genenta Science SpA ADR EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-7.71 USD
Jan 1, 2020
-3.96 USD
Jan 1, 2021
-0.33 USD
Jan 1, 2022
-1.30 USD
Jan 1, 2023
-1.85 USD
Jan 1, 2024
-4.30 USD
Jan 1, 2025
-2.76 USD
The Genenta Science SpA ADR EV/FCF history
YEAREV/FCFYoY
-2.76-35.89%
-4.30+132.78%
-1.85+41.64%
-1.30+300.66%
-0.33-91.78%
-3.96-48.61%
-7.71—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genenta Science SpA ADR Stock analysis

What does Genenta Science SpA ADR do? Genenta Science S.p.A. generates value by developing hematopoietic stem cell gene therapies for solid tumors in Italy. The company focuses on its product Temferon, which is currently in Phase 1/2a clinical trials for the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. Additionally, the firm is expanding the application of Temferon to other solid tumor indications. The business model relies on a proprietary biologic platform designed to deliver immunomodulatory molecules directly to tumors by infiltrating monocytes and macrophages. As a clinical-stage biotechnology company incorporated in 2014 and headquartered in Milan, Italy, Genenta Science S.p.A. utilizes this platform to advance its therapeutic pipeline and address unmet medical needs in oncology. Genenta Science SpA ADR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genenta Science SpA ADR stock

EV/FCF (Enterprise Value to Free Cash Flow) of Genenta Science SpA ADR is -2.76 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Genenta Science SpA ADR changed from -4.30 to -2.76, representing a -35.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Genenta Science SpA ADR since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Genenta Science SpA ADR with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Genenta Science SpA ADR

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Genenta Science SpA ADR